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Stroke attacks were found to be present at a younger age in patients from Southeast
Asia (SE) and the Middle East (ME) resident in the state of Qatar. Extracellular vesicles
(EVs), which are small membrane vesicles with pro-thrombotic properties, may contribute
to the high risk of stroke in this population. Thus, total and cell-specific medium size
EVs were counted by flow cytometry in platelet-free plasma from healthy volunteers and
patients with transient ischemic attacks (TIA) and acute ischemic stroke (AIS) from SE
and ME. Acutely, within 48 h of attacks, there was an increase in total endothelial EVs
in TIA (6.73 ± 1.77; P = 0.0156; n = 21) and AIS (11.23 ± 1.95; P = 0.0007; n =
66) patients compared to controls (2.04 ± 0.78; n = 24). Similar increases were also
evident in EVs originating from platelets, erythrocytes, granulocytes, and leukocytes.
Compared to controls, there was also an increase in EVs derived from activated
endothelial cells, platelets, granulocytes, leukocytes, and pro-coagulant EVs (Annexin
V+) at 5 and 30-days following the acute events, while a decrease was observed in
erythrocyte-derived EVs. This is the first study characterizing EVs in TIA and AIS patients
from ME and SE showing an increase in EVs associated with endothelial and platelet
cell activation, which may contribute to the elevated risk of stroke at a younger age in
this population.
Keywords: extracellular vesicles (EVs), acute ischemic stroke (AIS), transient ischemic attacks (TIA), thrombosis,
biomarkers
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INTRODUCTION
Acute ischemic stroke (AIS) is the leading cause of disability
and the second most common cause of death and dementia
worldwide. The incidence of AIS is particularly high in
Southeast Asia (SE) and the Middle East (ME) where the
prevalence of hypertension and diabetes is high and an increasing
proportion of the population are obese and suffer frommetabolic
syndrome (1–3).
Enhanced platelet aggregation and cell activation are
important contributors to the pathophysiology and progression
of AIS and are closely associated with stroke risk factors such
as hypertension and diabetes. In addition, loss of vascular
homeostasis and low-grade inflammation can further contribute
to endothelial dysfunction and atherogenesis, a primary factor
in the pathogenesis of AIS (4). In this context, circulating
extracellular vesicles (EVs), particularly the endoplasmic
membrane-derived microparticles or microvesicles, owing to
their crucial pro-coagulant role may contribute to the onset and
development of AIS (5).
EVs are membrane-containing vesicles that are released from
activated or apoptotic cells of any type. EVs are classified into
three main categories based on their size and their mechanism
of cellular release: exosomes (30–130 nm), microparticles or
microvesicles (100–1,000 nm), and the larger apoptotic bodies
(>1,000 nm) (6). Based on the most recent position statement
of the International Society for Extracellular Vesicles (ISEV), the
term EVs was adopted throughout this article as a generic term
to refer to lipid membrane-delineated, replication-defective, and
not carrying a functional nucleus, naturally cell-shed vesicles (7).
Elevated circulating levels of EVs, particularly those of medium
size (microparticles), were reported in many cardiovascular
diseases associated with inflammation and thrombotic alterations
including stroke and coronary artery disease (8, 9). Total
numbers of circulating EVs or those deriving from specific
cell populations were found to correlate with the presence
and severity of multiple disorders and are thus considered
as biomarkers for the monitoring of disease progression. For
instance, EVs originating from platelets were found to correlate
with atypical carotid intima/media thickness in obese patients
(10). In addition, high plasma numbers of pro-coagulant EVs
were reported in patients suffering from metabolic syndrome
(11, 12). Levels of EVs shed from endothelial cells (13) and
platelets (14) were reported to increase in AIS. In another study,
circulating EVs from platelets, endothelial cells, erythrocytes,
leukocytes, lymphocytes, monocytes, and smooth muscle cells
increased at the onset, and at 7 and 90 days in patients suspected
with AIS compared to controls (15). Recently, however, Landers-
Ramos et al. (16) reported that EVs levels of endothelial origin
were not increased in chronic stroke patients compared to
young and old healthy volunteers. Nonetheless, chronic stroke
patients also suffering from diabetes had higher plasma levels
of endothelial-derived EVs in comparison to those free of
diabetes (16).
Studies that have investigated EVs in stroke were mostly
conducted in small numbers of patients and in homogenous
ethnic populations. There are currently no reports available of
EVs in stroke patients from ME and SE. Furthermore, none of
the available studies has investigated the levels of circulating EVs
in patients with TIA, a major precursor and risk factor for AIS.
Another crucial point, is thatmost previous studies only looked at
the expression of select sub-populations of EVs in stroke patients.
The aim of the present study was therefore to count the
number of circulating medium size EVs and phenotype them
according to their cellular origins in patients with TIA and AIS
patients from SE and ME origins resident the state of Qatar,
at onset (within 48 h of attacks), 5 and 30-days following the
initiation of appropriate pharmacotherapy.
MATERIALS AND METHODS
Patients
The study was reviewed and approved by the Institutional Ethical
Board (IRB) of Hamad Medical Corporation (#15304/15) and
fully adhered to the principles of the declaration of Helsinki. All
participants of the study gave written informed consent prior to
their enrolment in the investigation. Patients were enrolled in
the study within 48 h of stroke onset. Individuals aged 18 years
and older and who gave written informed consent were included.
Stroke was defined according to World Health Organization
(WHO) criteria as “rapidly developing clinical signs of focal (or
global) disturbance of cerebral function, with symptoms lasting
24 h or longer or leading to death, with no apparent cause
other than vascular origin.” TIA was defined as a brief episode
of neurologic dysfunction resulting from transient cerebral
ischemia but that is not accompanied by cerebral infarction. All
AIS and TIA patients received at Hamad General hospital were
eligible for inclusion.
Data Collection
The baseline medical history includes age, gender, ethnicity,
nationality, marital status, household income, employment
status, smoking status, alcohol intake, medical comorbidities
(including a history of diabetes, dyslipidemia, coronary artery
disease, peripheral vascular disease, chronic kidney disease,
heart failure, and sleep apnea), and all current prescription and
over-the-counter medications (including dosage, frequency and
timing of administration). The cerebrovascular event type (AIS
vs. TIA) was documented using the Trial of Org 10,172 in Acute
Stroke Treatment (TOAST) classification and the date of stroke
was recorded. This information is currently recorded routinely in
the stroke database. We also recorded the type of work, duration
of time since they moved to Qatar (for expatriate subjects) and
the circumstances when the stroke occurred.
Physical examination included automated office blood
pressure (BP) [taken with a BPTru R© automated monitor by
measuring six readings in the arm with the higher BP, discarding
the first reading and averaging the latter two], height, weight,
and waist circumference.
Laboratory tests included a complete blood count, electrolytes
(sodium, potassium, chloride, total carbon dioxide), creatinine,
fasting glucose, glycated hemoglobin (A1c), fasting lipid profile,
c-reactive protein, and urine microalbumin. Computerized
tomography (CT) head scan, echocardiogram, and standard (not
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3D) carotid ultrasound results were performed as part of routine
clinical care at the time of stroke were recorded in the case
record forms (CRF). These tests are performed as part of routine
clinical care.
Isolation of Platelet-Free Plasma (PFP)
From Whole Blood
Peripheral venous blood (10mL) from control subjects, AIS,
and TIA patients was obtained in ethylenediaminetetraacetic
acid tubes (Vacutainers; Becton Dickinson) by using a 21-gauge
needle to reduce platelet stimulation. Samples were assayed
within 2 h of collection at room temperature. Blood samples were
then subjected low speed centrifugation (270 × g) for 20min to
separate platelet-rich plasma from whole blood. Following this,
platelet-rich plasma was centrifuged for further 20min at a speed
of 1,500 × g to collect PFP, which was then frozen and stored at
−80◦C until subsequent analysis for EVs content (11, 12, 17, 18).
Count and Identification of Cellular Origins
of EVs
Specific cellular subpopulations of medium size EVs were
identified in PFP according the expression of surface-specific
proteins as previously done by us (11, 12, 17, 18). Specific
fluorescent antibodies targeting the following surface antigens
were used in this study: PE-CD146 (endothelial cells), PE-CD41
(platelets), PC7-CD45 (leukocytes), PC7-CD235a (erythrocytes),
PE-CD62E (E-Selectin+ EVs), and PE-CD62P (P-Selectin+
EVs) (Beckman Coulter through Sedeer Medical, Doha, Qatar).
Irrelevant human IgG were used as isotype-matched negative
controls for each sample (Beckman Coulter). To count medium
size EVs and determine plasma concentrations for each cell
origin, separate assays for each surface marker were conducted.
Briefly, 10 µL of PFP from healthy controls or patients were
incubated with 5 µL of each specific antibody for 45min
protected from light. Then, samples were suspended in 300
µL of 0.9% saline solution and 10 µL Flowcount microbeads
(Beckman Coulter), a mix of fluorescent beads with known
concentration used to calculate absolute counts, were mixed
before samples were analyzed by flow cytometry using a BD
LSRFortessa analyzer (BDBiosciences, USA) as previously shown
by us (11, 12, 17, 18).
For the identification of the number of pro-coagulant EVs
(expressing phosphatidylserine), separate assays were conducted
to determine Annexin V binding. Briefly, 2 µL of Annexin V
(Beckman Coulter) were incubated with 5 µL PFP from each
participant for 30min protected from light. Then, samples were
suspended in 300 µL of Annexin-V labeling buffer, and 5 µL
(equal volume to sample) of Flowcount microbeads (Beckman
Coulter) were added before the analysis of samples by flow
cytometry using a BD LSRFortessa analyzer (BD Biosciences) as
previously shown by us (11, 12, 17, 18).
Statistical Data Analysis
Data are expressed as mean ± SEM or mean ± SD; n indicates
the number of subjects included in each experimental group.
Statistical analyses were performed by Mann-Whitney U or
analysis of one-way variance (ANOVA) for repeated measures
and subsequent Tukey’s post-hoc test. P < 0.05 was accepted as
statistically significant. Analyses were performed using GraphPad
Prism 7 software (GraphPad Software Inc., San Diego, USA).
RESULTS
Patients Baseline Characteristics
Between September 2016 and May 2018, we recruited 24 healthy
controls and a total of 119 patients with suspected acute stroke,
of whom 87 patients (66 [76%] AIS and 21 [24%] TIA) were
eventually included in the study after exclusion of stroke mimics.
The baseline characteristics of the 24 healthy volunteers and
the 87 patients included in the study are shown inTable 1. Similar
to previous experience, the average age in both TIA (48.6 ±
9.5) and AIS patients (50.5 ± 11.1) was young (3). The patient
population was predominantly male in AIS patients (95.5%). In
terms of disease classification, most AIS patients suffered from a
small vessel disease (59.1%), followed by cardio-embolic attacks
(16.7%) and large vessel disease (15.2%) (Table 1).
Total Number of Circulating of EVs and
Their Cellular Origins at Onset of Attacks
The count of total EVs regardless of their cellular origin did not
differ between controls, TIA and AIS patients (Figure 1) within
48 h of onset of attacks. TIA and AIS patients had significantly
higher percentage of circulating EVs derived from endothelial
cells (CD146+; Figure 2A) and activated endothelial cells that
express E-selectin (CD62E+; Figure 2B) compared to healthy
volunteers. Furthermore, there was a trend for AIS patients
to express more of total and activated endothelial-derived EVs
compared to TIA patients (Figures 2A,B).
Whereas, platelet-derived EVs (CD41+) were not significantly
different between controls, TIA, or AIS patients (Figure 2C),
the number of EVs derived from activated platelets expressing
P-selectin (CD62P+) was significantly higher in TIA and AIS
patients compared to controls (Figure 2D). Interestingly, AIS
patients exhibited a significantly higher percentage of activated
platelets-derived EVs compared to TIA patients (Figure 2D).
EVs derived from erythrocytes (CD235a+) were found to be
significantly higher in the blood from both TIA and AIS patients
compared to healthy volunteers (Figure 2E). Similarly, EVs
derived from circulating immune cells, granulocytes (CD66+;
Figure 2F) and leukocytes (CD45+; Figure 2G), were also
significantly higher in TIA andAIS patients compared to controls
although there was a non-significant trend for AIS patients
to express more of these two EV subtypes compared to TIA
patients (Figures 2F,G). Finally, the percentage of pro-coagulant
EVs expressing Annexin V at their surface was not significantly
different between the three groups within 48 h of onset of attacks
(Figure 2H).
The Total Number of EVs Increased Over
Time in AIS and TIA Patients as a
Percentage of Onset Levels
To investigate the impact of disease progression and the
initiation of treatment on the expression of EVs, we assessed the
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TABLE 1 | Baseline Characteristics of subjects enrolled in the study.
Controls (n = 24) Transient Ischemic Attack
(n = 21)
Acute Ischemic Stroke
(n = 66)
P value
Age (years) 47.7 ± 7.4 48.6 ± 9.5 50.5 ± 11.1 0.485
GENDER
Male 18 (75) 17 (81.0) 63 (95.5) 0.033
Female 6 (25) 4 (19.0) 3 (4.5)
ETHNICITY
ME 6 (29) 12 (57.1) 22 (33.3) 0.013
SE 18 (71) 9 (42.9) 44 (66.7)
Prior use of statins 0 7 (33.3) 8 (12.1) 0.025
Prior use of anti-hypertensive 0 6 (28.6) 12 (18.2) 0.306
Prior use of anti-diabetic medications 0 3 (14.3) 10 (15.2) 0.923
Diabetic on admission 0 7 (33.3) 27 (40.9) 0.535
Hypertensive on admission 0 13 (61.9) 45 (68.2) 0.595
Dyslipidemia on admission 0 15 (71.4) 38 (57.6) 0.257
Previous stroke 0 1 (4.8) 2 (3.0) 0.705
Coronary artery disease 0 2 (9.5) 6 (9.1) 0.952
Atrial fibrillation 0 1 (4.8) 3 (4.5) 0.967
Smoking history 0 6 (28.6) 29 (43.9) 0.211
IV thrombolysis received 0 2 (9.5) 12 (18.2) 0.347
PROGNOSIS AT DISCHARGE
Good (mRS 0–2) 21 (100.0) 48 (72.7) 0.007
Poor (mRS 3–6) 0.0 18 (27.3)
PROGNOSIS AT 90-DAYS
Good (mRS 0–2) 20 (95.2) 57 (86.4) 0.267
Poor (mRS 3–6) 1 (4.8) 9 (13.6)
TOAST CLASSIFICATION
Small vessel disease 39 (59.1)
Large vessel disease 10 (15.2)
Cardio-embolic 11 (16.7)
Stroke of determined origin 3 (4.5)
Stroke of undetermined origin 3 (4.5)
OTHER
Small vessel disease present 11 (52.4) 39 (59.1) 0.588
Silent infarct present 4 (19.0) 25 (37.9) 0.111
White matter ischemia present 14 (66.7) 52 (78.0) 0.258
Cerebral micro-bleeds present 4 (19.0) 20 (30.3) 0.315
Admission NIHSS 1.67 ± 2.1 3.35 ± 3.4 0.035
Systolic blood pressure 162.4 ± 26.1 157.4 ± 33.1 0.522
Diastolic blood pressure 94.7 ± 17.1 93.9 ± 21.0 0.883
Body Mass Index 27.6 ± 3.1 27.1 ± 3.9 0.634
HbA1c levels 6.4 ± 1.4 6.7 ± 2.1 0.545
Cholesterol levels 4.9 ± 1.3 5.2 ± 1.2 0.557
Triglyceride levels 1.9 ± 1.0 1.6 ± 0.9 0.353
HDL levels 1.1 ± 0.7 0.9 ± 0.2 0.031
LDL levels 3.1 ± 1.0 3.5 ± 1.0 0.086
Results are presented as mean ± SD or number (%) as appropriate. P-value from one-way ANOVA for quantitative variables and from Chi-square analysis for qualitative variables.
mRS, modified Rankin scale; NIHSS, national institutes of health stroke scale.
progression of numbers of total EVs over time at 5- and 30-days
post-attacks (Figure 3). The counts of EVs are expressed either
as absolute numbers or as percentage of increase compared to the
levels observed at onset of attacks for every patient. As shown
in Figure 3A, the absolute number of total EVs continued to
increase over time in both TIA and AIS patients, with the levels
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FIGURE 1 | Circulating total EV levels, at onset of attacks, in patients with TIA
and AIS compared to healthy controls. Histograms represent events/µL in
plasma poor in platelets (PFP) expressed as mean ± SEM. Controls, n = 24;
TIA, n = 21; AIS, n = 66.
at the 30-days’ time point being the most significant increase.
As observed in Figure 3B, the number of total EVs, expressed as
percentage of onset levels, also steadily increased over time at 5-
and 30-days post-attacks both in TIA and AIS patients.
EVs From Selected Cellular Origins
Increased Over Time Compared to
Onset Levels
The increase in EVs at 5- and 30-days post-attacks varied
depending on their cells of origin. TIA and AIS patients
had higher levels of EVs derived from endothelial (CD146+;
Figure 4A) and activated endothelial cells (CD62E+; Figure 4B)
at 5- and 30-days compared to onset levels. The increase
in EVs from activated endothelial cells (CD62E+; Figure 4B)
was highest in AIS patients, indicating a stronger activation
of endothelial cells as the disease progresses in AIS patients
compared to TIA patients. Similarly, EVs derived from both
platelets (CD41+; Figure 4C) and activated platelets (CD62P+;
Figure 4D) also significantly increased over time at 5- and
30-days in both TIA and AIS patients, indicating a sustained
activation of platelets despite appropriate treatment being
started. The expression of EVs derived from immune cells,
granulocytes (CD66b+; Figure 4F) and leukocytes (CD45+;
Figure 4G), also increased over time in both TIA and AIS
patients, indicating a sustained activation of these cell types on
the short-term following the start of pharmacotherapy. However,
the levels of erythrocyte-derived EVs (CD235a+; Figure 4E)
decreased significantly over time at 5- and 30-days post-attacks
in both TIA and AIS patients, suggesting a reduction in the
activation of these cells over time following the initiation
of therapy.
Although at onset of attacks, circulating levels of pro-
coagulant EVs (Annexin V+) were not different between
controls, TIA and AIS (Figure 2), the numbers of Annexin V+
EVs, expressed as a proportion of onset levels, increased with
time in both TIA and AIS patients at 5- and 30-days post-attacks
(Figure 4H), indicating that the shedding of pro-coagulant EVs
increased over time.
As a Proportion of Total EVs at Each Time
Point, the Initiation of Treatment Did Not
Affect the Short-Term Expression of EVs
Both in TIA and AIS Patients
As shown in Figure 5, the levels of circulating EVs, expressed
as a percentage of total EVs at each time point, from all the
cell origins investigated did not change in AIS patients over the
monitored period (5- and 30-days post-attacks). Similar pattern
was observed with TIA patients, where circulating levels of EVs
from all cell origins studied did not vary, as a percentage of
total EVs for each time point, after 5- and 30-days following
the initiation of the pharmacotherapy (Figure 6). These data
demonstrate that, as a percentage of total EVs at each time
point, circulating levels of EVs from various cellular origins were
constant over time (at 5- and 30-days) although their numbers
have increased compared to onset time point. The increased
number of total EVs over time drives the increase of specific
populations of EVs without affecting their overall proportion in
blood. Together, these findings further indicate that in both TIA
and AIS patients, cellular activation continued to be elevated on
the short-term despite the management of risk factors and the
administration of appropriate pharmacotherapy to the patients.
DISCUSSION
For many decades, EVs were considered as inert cell debris
or platelet dust derived from platelets which are rich in
phospholipids and endowed of pro-coagulant capacity (8). Later,
it was found that EVs could transport cargo content including
secretable and non-secretable biological molecules such as active
lipids, nucleic acids (microRNA and mRNA) in addition to
membrane and cytosolic proteins to target cells (8, 19, 20).
Circulating EVs derive from platelets, red and white blood cells,
endothelial cells, andmonocytes; however, most EVs found in the
blood are from platelet origin (8, 9). EVs regulate inflammation
and have pro-coagulant properties (21). Plasma numbers of
EVs are elevated in cardiovascular disorders associated with
thrombotic alterations including stroke and coronary artery
disease (8, 9). Plasma levels of total EVs or those deriving from
specific cell populations were found to correlate with the presence
and severity of multiple disorders and are thus considered as
biomarkers for the monitoring of disease progression and hence
can provide a signature for changes occurring inside the body
(11, 12, 22).
We report in the current study that although the total number
of EVs did not differ between TIA and AIS patients compared to
controls within 48 h of attacks onset, both TIA and AIS patients
had higher circulating levels of EVs derived from endothelial
cells (CD146+), activated endothelial cells (CD62E+), activated
platelets (CD62P+), granulocytes (CD66b+), and leukocytes
(CD45+) compared to controls; however, AIS patients had higher
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FIGURE 2 | Circulating EV levels, expressed as percentage of total EVs, at onset of attacks, in patients with TIA and AIS compared to healthy controls. Histograms
represent circulating levels of EVs derived from: (A) endothelial cells (CD146+), (B) activated endothelial cells (CD62E+), (C) platelets (CD41), (D) activated platelets
(CD62P+), (E) erythrocytes (CD235a+), (F) granulocytes (CD66b+), (G) leukocytes (CD45+), (H) and pro-coagulant (Annexin V+) origins. Histograms represent
events/µL (% of total EVs) in PFP expressed as mean ± SEM. Controls, n = 24; TIA, n = 21; AIS, n = 66. *P < 0.05, **P < 0.01, ***P < 0.001 vs. controls;
#P < 0.05 vs. TIA.
FIGURE 3 | Circulating total EV levels, at onset, 5-days and 30-days post-attacks in patients with TIA and AIS patients. (A) Histograms represent total EVs expressed
as events/µL in PFP. (B) Histograms represent total EVs expressed as events/µL (% of onset levels) in PFP. Data are expressed as mean ± SEM. Controls, n = 24;
TIA, n = 21; AIS, n = 66. *P < 0.05 vs. indicated groups.
numbers compared to TIA patients. While there are few reports
regarding the phenotype of expression of circulating EVs in AIS,
there is a severe paucity of information regarding EVs numbers
in blood from TIA patients and how they differ compared to AIS
patients. To the best of our knowledge, this is the first report
to determine circulating levels of EVs from various cell origins
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FIGURE 4 | Circulating EV levels, expressed as events/µL (% of onset levels), at onset, 5-days and 30-days post attacks, in PFP from patients with TIA and AIS.
Histograms represent circulating levels of EVs derived from: (A) endothelial cells (CD146+), (B) activated endothelial cells (CD62E+), (C) platelets (CD41), (D)
activated platelets (CD62P+), (E) erythrocytes (CD235a+), (F) granulocytes (CD66b+), (G) leukocytes (CD45+), (H) and pro-coagulant (Annexin V+) origins. Data are
expressed as mean ± SEM. Controls, n = 24; TIA, n = 21; AIS, n = 66. *P < 0.05, **P < 0.01 vs. indicated groups.
in TIA patients and compare them to AIS patients and healthy
controls. Only one previous publication could be found reporting
increased levels of platelet-derived EVs in TIA compared to
controls (23).
In relation to AIS, our findings are partly in agreement with
the few previous studies which investigated EVs levels in AIS
patients. Li et al. (13) have studied EVs in a cohort composed
of patients with AIS and gender-matched healthy volunteers.
In accordance with our data, authors reported that patients
had higher levels of endothelial-derived EVs and EVs carrying
markers of cell activation (CD62E+); however, no differences in
platelet-derived EVs were noted (13). Another study, reported
in a cohort of AIS patients that platelet-derived EVs were,
however, increased compared to control subjects (14). Recently,
it was observed that plasma levels of endothelial-derived EVs
were not increased in chronic stroke patients compared to
younger and old healthy volunteers (16). These findings are
in contrast with our observations and the discrepancy may be
attributable to the ethnic differences between the study cohorts
[Chinese in Chen et al. (14) vs. SE and ME in our study].
In addition, the study by Chen et al. (14), determined the
levels of platelet-derived EVs using anti-CD61 antibody, while
in our study we have used an anti-CD41 antibody. Both CD41
and CD61 are platelet-specific glycoproteins, which were widely
used as surface markers for the detection of EVs from platelet
origin (24, 25). However, in our hands, we have observed
similar results to those observed with CD41 when CD61 was
used as a surface marker to detect platelet-derived EVs (data
not shown for CD61) and hence the discrepancy between the
two studies may be more related to the ethnic differences in
study populations.
More recently, circulating EVs from platelets, endothelial
cells, erythrocytes, leukocytes, lymphocytes, monocytes, and
smoothmuscle cells were analyzed in patients with suspected AIS
at the onset of attacks, and then at 7 and 90 days. In line with
our observations reported here, authors observed that EVs from
all these cell origins were increased in stroke patients compared
to controls at onset of attacks and that their levels remained
high at 7 and 90 days following the acute events (15). In our
hands, we observed that, by contrast to Chiva-Blanch et al. (15),
the number of EVs from endothelial cells, activated endothelial
cells, platelets, activated platelets, granulocytes, leukocytes, and
pro-coagulant origin, expressed as percentage of onset levels,
all increased in both TIA and AIS patients after 5 and 30
days post-attacks and the initiation of treatment and the
management of risk factors (e.g., diabetes or hypertension).
These data, show an escalated cell activation, particularly in
endothelial cells and platelets, acutely after the attacks in both
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FIGURE 5 | Circulating EV levels, expressed as events/µL (% of total EVs), at onset, 5-days and 30-days post-attacks in PFP from patients with AIS. Histograms
represent circulating levels of EVs derived from: (A) endothelial cells (CD146+), (B) activated endothelial cells (CD62E+), (C) platelets (CD41), (D) activated platelets
(CD62P+), (E) erythrocytes (CD235a+), (F) granulocytes (CD66b+), (G) leukocytes (CD45+), (H) and pro-coagulant (Annexin V+) origins. Data are expressed as
mean ± SEM. AIS, n = 66.
TIA and AIS patients, which may contribute to heightened
endothelial and pro-thrombotic activities contributing thus to
an elevated risk of stroke recurrence. However, we cannot
rule out that the elevation of EVs levels following the attacks
and the start of pharmacotherapy might be related to the
resolution of thrombi and the secondary consequences of
ischemic episodes. Thus, a longer follow-up of these patients
is warranted to determine the long-term changes of EVs
and further ascertain the prognostic value of circulating EVs
levels in TIA and AIS patients with regards to the risk
of recurrence.
Of particular interest, in our study, plasma levels of EVs
from platelets (CD41+), activated platelets (CD62P+), and pro-
coagulant (Annexin V+) origins increased, as a percentage of
onset numbers, on the short-term (at 5- and 30-days after
acute attacks), indicating a higher number of EVs with pro-
thrombotic activity, which may contribute to the increased risk
of recurrence of stroke in these patients, including those with no
major consequences (TIA). EVs from platelet origin are indeed
strongly pro-thrombotic (21). It has been reported that one single
platelet-derived EV had nearly the same pro-coagulant activity
as one activated platelet despite the surface area was 2 orders of
magnitude smaller, suggesting that the surface of platelet-derived
EVs is 50 to 100–fold more pro-coagulant than that of activated
platelets (26). Furthermore, though not directly assessed in this
study, EVs expressing tissue factor (TF) may also enhance the
coagulation process in stroke patients. EVs carrying TF were
found to be highly expressed in several ischemic conditions such
as atherosclerosis and acute coronary syndromes (27). It was
reported that the expression of TF at the surface of EVs enhanced
their pro-coagulant response (28). Higher circulating levels of
EVs expressing TF were observed in AIS patients compared
to healthy controls. Moreover, 1 week after the diagnosis, the
activity of EVs was found to be more elevated in stroke patients
not treated with tissue plasminogen activator compared to their
basal activity at the onset of attacks (29).
While we have observed that erythrocyte-derided EVs
(CD235a+) were increased to the same extent in both TIA
and AIS compared to controls within 48 h of onset of attacks,
we found that their levels, expressed as a proportion of
onset levels, decreased in both TIA and AIS patients at 5-
and 30-days following the initiation of pharmacotherapy. In
contrast with our observation, Chiva-Blanch et al. (15), found
that erythrocyte-derived EVs were higher in AIS patients
compared to controls and continued to be high at 7 and
90 days post-stroke attacks (15). Our data suggest that the
administration of treatment to patients led to a decrease
in the expression of erythrocyte-derided EVs, which were
previously linked to hypercoagulable states. Consistent with our
observations, Tan et al. (30), observed that high circulating
levels of phosphatidylserine-positive erythrocyte-derived EVs,
which were highly pro-coagulant, in patients suffering from
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FIGURE 6 | Circulating EV levels, expressed as events/µL (% of total EVs), at onset, 5-days and 30-days post-attacks in PFP from patients with TIA. Histograms
represent circulating levels of EVs derived from: (A) endothelial cells (CD146+), (B) activated endothelial cells (CD62E+), (C) platelets (CD41), (D) activated platelets
(CD62P+), (E) erythrocytes (CD235a+), (F) granulocytes (CD66b+), (G) leukocytes (CD45+), (H) and pro-coagulant (Annexin V+) origins. Data are expressed as
mean ± SEM. TIA, n = 21.
the hypercoagulable status of polycythemia vera and that the
treatment of patients with hydroxyurea was associated with a
decrease in the shedding of EVs from erythrocytes (30).
Our data characterized for the first time circulating EVs in
patients with AIS and compared them to TIA in a multiethnic
population from SE and ME origins. We provided here, a very
comprehensive analysis of most circulating EVs from vascular
wall, blood, and immune cells. We found here that EVs of various
origins, especially those associated with endothelial cell injury
and platelet activation, are increased in TIA and AIS patients
and that their levels persist to be high on the short-term up to
30-days post-attacks, indicating a sustained cellular activation,
which may be associated with a heightened risk of recurrence of
acute events. Therefore, longer follow-up studies are required to
ascertain the value of EVs as biomarkers for the risk of stroke
recurrence, especially in a population presenting with stroke at
young age like this one.
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